Shield Therapeutics (LON:STX) Stock Price Crosses Below Fifty Day Moving Average – Here’s Why

Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 8.26 and traded as low as GBX 6.55. Shield Therapeutics shares last traded at GBX 6.60, with a volume of 3,824,224 shares trading hands.

Shield Therapeutics Stock Up 0.1%

The firm has a 50 day moving average of GBX 8.26 and a two-hundred day moving average of GBX 9.18. The firm has a market capitalization of £71.53 million, a price-to-earnings ratio of -3.35 and a beta of 1.88. The company has a quick ratio of 2.16, a current ratio of 0.90 and a debt-to-equity ratio of -199.87.

About Shield Therapeutics

(Get Free Report)

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.

See Also

• Five stocks we like better than Shield Therapeutics
• Why Applied Optoelectronics Stock May Be Near a Turning Point
• From High-Yield to High-Growth: 3 Stocks Boosting Dividends
• Is Everspin Technologies the Next AI Edge Breakout?
• 5 Robotics Stocks to Watch as Physical AI Builds Momentum

Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.